AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
_6ff029a61766633234293.png?format=webp&width=1186&height=250)
Cellectar Biosciences' Stock Price Adjusted to $18 by Roth Capital
ByAinvest
Thursday, Aug 14, 2025 9:31 pm ET1min read
Roth Capital adjusts its target price for Cellectar Biosciences to $18 from $3, citing the company's reverse stock split. Despite the change, the firm maintains a Buy rating on the shares.
Roth Capital Partners has revised its target price for Cellectar Biosciences (CLRB) to $18 from $3, citing the company's recent reverse stock split. Despite the significant adjustment, the firm maintains a Buy rating on the shares. The move reflects Roth Capital's optimism about Cellectar Biosciences' potential and its commitment to the company's long-term prospects.Cellectar Biosciences, a late-stage clinical biopharmaceutical company, focuses on the development of phospholipid drug conjugates (PDCs) for cancer treatment and imaging. Its portfolio includes CLR 131, CLR 125, CLR 124, and CLR 1502, each targeting various types of cancer. The company is scheduled to release its Q2 2025 earnings on August 14, with analysts expecting an EPS of $-3.66 [2].
The reverse stock split, which took effect on July 1, 2025, is designed to simplify Cellectar Biosciences' stock structure and potentially attract new investors. As of June 30, 2025, the company reported a GAAP EPS of -$3.39, beating the estimated -$3.70 by $0.31 [3]. The company also announced a one-for-thirty reverse stock split, which will reduce the number of outstanding shares from approximately 100 million to 3.33 million.
Roth Capital's decision to maintain a Buy rating indicates confidence in Cellectar Biosciences' pipeline and future prospects. The firm believes that the reverse stock split will enhance the company's liquidity and attractiveness to institutional investors. However, the stock has experienced a significant decline over the past 52 weeks, with a 92.69% decrease in share price [2].
Investors are encouraged to monitor Cellectar Biosciences' upcoming earnings release and any subsequent guidance for further insights into the company's performance and future prospects. As always, it is essential to conduct thorough research and consider multiple factors before making investment decisions.
References:
[1] https://www.cnn.com/markets/stocks/CLRB
[2] https://www.ainvest.com/news/cellectar-biosciences-q2-2025-earnings-preview-analysts-expect-3-66-eps-2508/
[3] https://seekingalpha.com/news/4485266-cellectar-biosciences-gaap-eps-of-3_39-beats-by-0_31
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet